Ricardo Restrepo-Jaramillo
Overview
Explore the profile of Ricardo Restrepo-Jaramillo including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
12
Citations
244
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Tourki B, Jia M, Karampitsakos T, Vera I, Arsenault A, Fatima Z, et al.
Am J Physiol Cell Physiol
. 2024 Nov;
328(1):C199-C211.
PMID: 39510135
We aimed to study transcriptional and phenotypic changes in circulating immune cells associated with increased risk of mortality in COVID-19, resolution of pulmonary fibrosis in post-COVID-19-interstitial lung disease (ILD), and...
2.
Kim N, Chin K, McLaughlin V, Dubrock H, Restrepo-Jaramillo R, Safdar Z, et al.
Pulm Ther
. 2024 Jan;
10(1):85-107.
PMID: 38184507
Introduction: Portopulmonary hypertension (PoPH) carries a worse prognosis than other forms of pulmonary arterial hypertension (PAH). Data regarding use of PAH-specific therapies in patients with PoPH are sparse as they...
3.
Waxman A, Restrepo-Jaramillo R, Thenappan T, Engel P, Bajwa A, Ravichandran A, et al.
Eur Respir J
. 2023 Apr;
61(6).
PMID: 37080567
Introduction: The 16-week randomised, placebo-controlled INCREASE trial (RCT) met its primary end-point by improving 6-min walk distance (6MWD) in patients receiving inhaled treprostinil for pulmonary hypertension due to interstitial lung...
4.
Spikes L, Bajwa A, Burger C, Desai S, Eggert M, El-Kersh K, et al.
Pulm Circ
. 2022 May;
12(2):e12063.
PMID: 35514770
Inhaled treprostinil is an approved therapy for pulmonary arterial hypertension (PAH) and pulmonary hypertension associated with interstitial lung disease in the United States. Studies have confirmed the robust benefits and...
5.
Rahaghi F, Balasubramanian V, Bourge R, Burger C, Chakinala M, Eggert M, et al.
Pulm Circ
. 2022 May;
12(2):e12055.
PMID: 35514769
Dual combination therapy with a phosphodiesterase-5 inhibitor (PDE5i) and endothelin receptor antagonist is recommended for most patients with intermediate-risk pulmonary arterial hypertension (PAH). The RESPITE and REPLACE studies suggest that...
6.
Orozco-Levi M, Caneva J, Fernandes C, Restrepo-Jaramillo R, Zayas N, Conde R, et al.
Pulm Circ
. 2022 May;
12(1):e12012.
PMID: 35506085
Treatment for pulmonary arterial hypertension and chronic thromboembolic pulmonary hypertension in Latin America differs between countries, with regard to disease etiology, health insurance coverage, and drug availability. A group of...
7.
Bandyopadhyay D, Lai C, Pulido J, Restrepo-Jaramillo R, Tonelli A, Humbert M
Eur Respir Rev
. 2021 Dec;
30(162).
PMID: 34937705
Pulmonary hypertension (PH) confers a significant challenge in perioperative care. It is associated with substantial morbidity and mortality. A considerable amount of information about management of patients with PH has...
8.
Shapiro S, Mandras S, Restrepo-Jaramillo R, Shen E, Broderick M, Rao Y, et al.
Pulm Circ
. 2021 Nov;
11(4):20458940211052228.
PMID: 34733493
Treprostinil is a prostacyclin approved for the treatment of pulmonary arterial hypertension. Commercial data sets indicate that approximately 20-25% of patients are prescribed a higher dose than the maximum recommended...
9.
Zwicke D, Restrepo-Jaramillo R, Alnuaimat H, Gordon K, Broderick M, Edwards L, et al.
Pulm Circ
. 2021 Mar;
11(1):2045894021998203.
PMID: 33738096
Oral treprostinil has recently been shown to delay disease progression in patients with pulmonary arterial hypertension in a long-term outcomes study. The potential advantages of an oral formulation have resulted...
10.
Waxman A, Restrepo-Jaramillo R, Thenappan T, Ravichandran A, Engel P, Bajwa A, et al.
N Engl J Med
. 2021 Jan;
384(4):325-334.
PMID: 33440084
Background: No therapies are currently approved for the treatment of pulmonary hypertension in patients with interstitial lung disease. The safety and efficacy of inhaled treprostinil for patients with this condition...